Cancer jab to speed up treatment for patients

The immunotherapy is usually given intravenously.
Atezolizumab is usually given to patients intravenously but now many patients in England are to be given the immunotherapy via an injection (PA)
PA Archive
Ella Pickover29 August 2023

Hundreds of NHS patients are to get swifter treatment thanks to the approval of a cancer jab.

Atezolizumab is usually given to patients intravenously (via an IV drip) but now many patients in England are to be given the immunotherapy via an injection.

The drug, also known as Tecentriq, is a treatment for a number of different types of cancer, including lung, breast, liver and bladder cancers, and it is given to around 3,600 patients in England each year.

It is expected that the majority of these people will now get the drug via a seven-minute injection instead of intravenously, which usually takes 30 minutes to an hour.

The world-first introduction of this treatment will mean that hundreds of patients can spend less time at the hospital and will free up valuable time in NHS chemotherapy units

Professor Peter Johnson, NHS England

Patients who receive atezolizumab alongside chemotherapy may still be given the drug intravenously.

The drug is known as a “checkpoint inhibitor” and works by helping the immune system find and kill cancer cells.

The NHS in England said it has become the first health system in the world to roll out the injection version of the drug after it was approved for use by the Medicines and Healthcare products Regulatory Agency.

NHS England’s national director for cancer Professor Peter Johnson said: “The world-first introduction of this treatment will mean that hundreds of patients can spend less time at the hospital and will free up valuable time in NHS chemotherapy units.

“Maintaining the best possible quality of life for cancer patients is vital, so the introduction of faster under-the-skin injections will make an important difference.”

Marius Scholtz, medical director for Roche Products Limited, which manufactures the jab, said: “Injecting Tecentriq under the skin offers a faster treatment option as it takes approximately seven minutes, compared with 30 to 60 minutes for the current method of an intravenous infusion of Tecentriq.

“We are delighted that NHS patients across England have access to the subcutaneous PD-L1 cancer immunotherapy injection.”

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in

MORE ABOUT